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Abstract. The progress of the prostate-specific antigen after radical prostatectomy
is observed for a patient in order to extract information on the growth mode of the
tumor cells. An initial fast-growth mode goes over to a slower power-law regime within
two years of surgery. We argue that such studies may help determine the appropriate
time window for subsequent therapies in order to increase the life expectancy of the
patient.
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1. Introduction
The cancer of the prostate gland is one of the most frequently diagnosed male illnesses
that may lead to the death of individuals older than 50. There are two major causes
for the dramatic increase in the number of men diagnosed with prostate cancer every
year: i) a straight-forward blood test became available measuring a glycoprotein called
prostate-specific antigen (PSA) to detect prostate carcinoma, ii) by virtue of advancing
medical techniques, the increasing life expectancy exposes a higher male population to
the disease.
The PSA test is a statistical decision-making tool. While it detects true-positive
cases with ease, the false-negative outcome is not nil and may have a lethal consequence.
Hence, a biopsy of the gland provides a “second opinion”. In the case of positive
outcome of the biopsy, statistical predictions are used to assess the status of the tumor,
its classification, and the extent of its progression. If the result of the PSA test turns
out to be a false alarm, the inconvenience of the biopsy is the consequence.
At an early stage of the cancer growth with a localized tumor, a radical removal
of the prostate gland is preferred for younger patients. It is generally believed that a
conformal radiation therapy may be as effective, however, in the case of elder individuals.
For cases of progressed tumor, palliative measures are preferred including hormonal
therapy to retard the growth of the prostate cancer. Findings of the last few years based
on long-term statistics suggest a longer life expectancy for patients with postoperative
radiotherapy that follows (within 6 months of) the radical prostate surgery (see, e.g.,
Cozzarini et al 2004, Bolla et al 2005). Albeit known to cause adverse side effects, this
strategy may certainly prove profitable for patients with some higher risks, like prostate
capsule perforation or involvement of seminal vesicles or lymph-nodes.
Different alternatives for treatment after radical removal of the prostate gland are
currently under debate if the PSA values rise after the surgery. Commonly, a standard
radiotherapy is applied after the PSA level reaches a predetermined threshold value.
However, a wait-and-watch method may cause loss of valuable time and miss the relevant
moment of action regardless of how low the threshold value is set.
It has already been suggested by many authors over the years (Schabel 1969, Bru´ et
al 2003, Kohandel et al 2007, these references are only a sample and do not in any way
claim to be exhaustive), that the entire course of growth of the tumors offers important
information regarding the clinical strategies to be followed. Here we would like to point
out a number of features of the the post-operative temporal progression of PSA values
which could help make a clearer decision about the strategic time window for combined
therapies on these cells.
The purpose of this work is three-fold: a) point to the possibility of detecting fast
(exponential) growth of the PSA scores, much before an arbitrary threshold value is
reached, thus gaining time in making decisions regarding therapies to be followed, b)
re-analyze PSA data in a way which reveals a sharp crossover from exponential to power-
law growth c) propose a simple model to explain the crossover to slower (power-law)
Tracking tumor evolution via the prostate marker PSA 3
growth.
The second, slower growth regime, we argue, arises due to the coalescence or
“condensation” (Torkington 1983) of freely dividing cancerous cells to form one or more
compact tumors, with growth essentially confined to the edges or the surface (Bru´ et
al 2003, Kansal et al 2000, Delsanto et al 2004, Kohandal et al 2007). It has been
pointed out that at this stage “sensitivity to anti-metabolic drugs decreases,. . . (since
the fraction of) tumor cells that are in the cell division cycle decreases” (Schabel 1969).
It is only subsequent to this crossover that processes such as angiogenesis (Kohandel et
al 2007) can come into play.
2. Results
After a radical prostatovesiculectomy (pT2c N0 M0 G2, Gleason 3+4 = 7) applied to one
of us (ME), PSA values have been determined using constant laboratory conditions at
time intervals of initially 6 months. These values are presented in Table 1. The estimated
error for the dates of measurement is ±1 week, while the PSA values are determined
with the state-of-the-art precision, with error bars of the order of ±0.002 µg/l. In
Fig. 1 we plot all the values listed in the table as a function of time in months after
the surgery. The temporal increase of the PSA scores has a characteristic “U” shape,
i.e., a shallow increase during the first two years and a steep rise in the last two. In
current practice, each datum point at a particular time is used by the physician to assess
the patient’s health condition and to decide upon further action. Here we show that
the functional form of this curve can be determined at an early stage which provides
Table 1. The PSA values and the dates of measurement after the operation in March
2003 as well as the time elapsed thereafter in months. The errors in determining the
PSA values are ±0.002 µg/l, while the time elapsed after the operation may err by at
most ±1 week.
Date of the Time after the PSA score
PSA test operation (months) (µg/l)
Aug. 2003 5 0.006
Feb. 2004 11 0.012
Aug. 2004 17 0.019
Feb. 2005 23 0.037
Aug. 2005 29 0.044
Feb. 2006 35 0.099
Aug. 2006 41 0.170
Nov. 2006 44 0.144
Feb. 2007 47 0.168
May 2007 50 0.294
Jul. 2007 52 0.262
Feb. 2008 59 0.295
Aug. 2008 65 0.485
Tracking tumor evolution via the prostate marker PSA 4
Figure 1. PSA values in µg/l are displayed as a function of measurement time in
months after the surgery.
crucially important information on the stage of progression of the disease.
In order to detect the kinetics of cell growth underlying the PSA progression, we
present in Fig. 2(a) the same PSA values as a function of time, but plotted on a
logarithmic scale. We observe a linear increase starting at the time of surgery until
about 40 months thereafter. Analytically this corresponds to “exponential growth,”
with the functional form ∼ exp(at), where a is a constant rate of reproduction. Later
values remain below the straight line, implying a different, slower growth law.
We examine more closely the crossover from exponential behavior in the real PSA
data given in Table 1 by re-plotting the values against the number of months after the
surgery, this time with both axes in the logarithmic scale. In this log-log plot, a power-
law behavior in time (i.e., having the functional form ∼ tu) is represented by a straight
line. Fig. 2(b) shows the results and indicates that the crossover observed in Fig. 2(a)
at about two years after the surgery is remarkably sharp, rather than being a gradual
slowing down. From this point on, up to the last measured value, the PSA values grow
as a power of the time elapsed after the crossover point.
3. Procedures
3.1. Growth modes
We assume that the PSA value in µg/l is linearly proportional to the number N of
carcinoma cells. We also assume that each cell divides with a constant rate p (probability
per unit time), so that N cells give birth to pN new cells per unit time, on the
average. The cells can be located at different places in the tissue and may migrate
upon multiplication. For such unrestricted growth, the differential equation is
dN/dt = pN . (1)
Tracking tumor evolution via the prostate marker PSA 5
Figure 2. PSA values plotted on a logarithmic scale against a) linear time and b)
against time on a logarithmic scale. Note that the straight line fit in panel (a) signals
exponential growth, while in panel (b), “power law” growth (see text). The vertical
size of the first four points indicates the estimated error, while in the subsequent points
the error bars are smaller than the size of the plotted points.
Integrating Eq. 1, we obtain the number of cells at any time t from the start of the
growth process, given their initial value N0, to be
N(t) = N0 exp(pt) . (2)
This type of growth is unrestricted, the birth of a new cell has no effect on that
of subsequent cells. This scenario probably holds true especially at the initial stages
of growth for small values of malignant cell concentration. When the number N of
malignant cells grows within the tissue, higher concentrations will arise. We would like
to argue that this process results in the spontaneous formation of macroscopic clusters of
cells (which we will call tumors) which mop up almost all of the microscopic clusters, at
a rather sharp transition point called the percolation transition (Stauffer and Aharony
1992), and which occurs here at a given concentration of sick vs healthy cells within a
given region.
At the percolation threshold (Stauffer and Aharony 1992), the clusters will be
fractal (Mandelbrot 1983). For fractal clusters one will have the radius of gyration (a
measure of the average radius) Rg ∼ N
1/D, with D < 3 being the fractal dimension,
and N is total number of sick cells within the tumor. It is also known that with more
than one condensation site, one may have cluster-cluster aggregation which leads once
again to fractal clusters (Kolb et al 1983). Were the growth to continue at sites within
this porous, fractal cluster, with the concentration of sick cells growing beyond the
percolation threshold, the resulting objects would be compact, with D → 3.
It seems that simply due to spatial constraints (Kansal et al 2000), or under-
nourishment and under-oxygenation (hypoxia) of the interior (Kohandel et al 2007),
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growth is confined essentially to the surface of the macroscopic clusters. For growth
confined to the surface of the tumor, the kinetic equations should involve the number
Ns of actively dividing cells in the surface layer, which scales as the surface area. Thus,
Ns ∼ R
Ds
g , with Ds being the surface dimension. If the surface area can be said to grow
as the radial derivative of the total mass, Ds = D − 1. Then, Ns ∼ R
Ds ∼ NDs/D.
The kinetic equation becomes, in the most general case where D ≤ 3,
dN/dt = p k1R
Ds
g = p k2N
Ds/D , (3)
where k1 and k2 are constants involving geometrical factors. Integration yields,
N = (c1 + c2t)
u , (4)
where u = D/(D−Ds), c1 = uN
1/u
0 , with N0 having the same meaning as in Eq. 1, and
c2 = p k2. Independently of the exact value of the exponent, the behavior predicted by
Eq. 4 certainly points to a time dependence that is a power law, for c1 small enough.
This analysis predicts a power-law growth, in all cases where the growth is
essentially confined to the surface region of the tumors. Note that for ordinary compact
objects with smooth surfaces, Ds = 2; for this value Eq. 3 will give the expected growth
rate for spheroidal tumors (Delsanto et al 2004) and one gets u = 3. In the case that
Ds tends to D, meaning that all cells are free to multiply at the same rate, Eq. 3 will
of course tend to Eq. 1, with k2 → 1. For percolation clusters growing only along an
outer shell (and not along the boundary or the “hull” (Stauffer and Aharony 1992) of
the highly convoluted cluster (Cao and Wong 1992)), one has precisely u = D, with
D ≃ 2.5 in three dimensions (Stauffer and Aharony 1992).
A slightly different growth scenario is provided by the Eden model (Eden 1961,
Jullien and Botet 1985, Wolf and Kerte´sz 1987, Family and Vicsek 1991, Meakin 1999).
Growth starts from a seed or a surface, and one assumes that each cell within the surface
layer has an equal probability to give rise to a daughter cell and the cells within the
tumor multiply with a probability that is negligible, as recent results also show (Bru´ et
al 2003, Delsanto et al 2004, Kansal et al 2000). This growth rule is known to be in the
same class of growth problems as the celebrated Kardar, Parisi, Zhang model (Kardar et
al 1986) of surface growth (Batchelor et al 1998). The Eden model gives rise to compact
tumors (D = 3), with rough surfaces. Although the surface is known to be self-affine,
within a simplified fractal picture the surface area can be thought of as scaling with
the average radius as RDsg , where Ds > 2 is the fractal dimension of the surface. The
precise value of Ds is under some debate. The width w of the fluctuating surface region
is known to scale as w ∼ Rβg (Batchelor et al 1998), with β = 0.1 (Kuennen and Wang
2008), yielding Ds = 2 + β = 2.1. Alternatively Ds may be estimated as 3 − α = 2.3,
with the so called roughness exponent α = 0.7 (Meakin 1999). Substituting these values
in Eq. 4, Eden growth predicts a growth exponent u = 3.3, or 4.3, depending upon the
estimate for Ds.
Clearly, this discussion does not exclude the possibility that upon further growth
other mechanisms for inhibition or enhancement of the growth can come into play
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and that the growth regime will be further modified in qualitative agreement with the
Gompertzian growth curve.
3.2. Data analysis
Fig. 2(a) confirms an exponential growth of the initial PSA scores with a starting value
of 0.0042 µg/l. The growth rate corresponds to p = 0.09 ± 0.004 per month. In
everyday language, the PSA doubling time is about 8 months (the doubling time in
months is here given by (ln 2)/p); in other words, the PSA score increases more than
three times within a year. Although the absolute PSA values are much lower than the
widely accepted threshold values for the recurrence of the prostate cancer, the growth
rate is alarmingly fast. Yet, after about three years, the growth rate slows down and
deviates from the exponential behavior. Nevertheless, an arbitrarily set threshold will
be approached gradually.
Fig. 2(b) is a log-log plot of the PSA values against the time. We observe that
about two years after the operation there is a transition from unrestricted cell division
at constant rate, characterized by exponential growth, to a power law signalling the
formation of clusters and possibly the initiation of angiogenesis. The exponent of
u = 2.57± 0.07 is very close to the value predicted above, for percolation clusters with
growth confined to an outer shell. We cannot, of course, rule out the Eden scenario
based on just this result. It is possible that the effective number of surface cells is
smaller than our naive estimation, thus giving rise to an overestimation of Ds, and
therefore of u, in this case. Once the switch to power law growth occurs, signaling
discrete, more or less compact tumors, we can estimate their size if the relation between
the total number of cancerous cells and the PSA value is known. Assuming that the
PSA level is linearly proportional to the total number of malignant cells, the PSA value
and tumor size obtained from magnetic-resonance imaging (MRI) at the time of the
operation provide our points of reference. In the present case, the prostate gland was
imaged prior to its removal in August 2002 at a time when the PSA value was 8.5 µg/l.
The gland had a diameter of less than 40 mm (Huber 2002). Taking into account the
fact that the gland was about 50% cancerous according to the post-operative biopsy, we
deduced that a PSA level of 0.485 µg/l, measured in August 2008, would correspond to a
tumor (consisting only of cancerous cells) of approximately 5 mm in diameter. Allowing
for the possibility that not one, but two equal size compact clusters condense out of the
scatter of individual cells, our naive calculation would give a diameter of approximately
4 mm for these tumors.
It is highly significant that, digital rectal examinations by three independent experts
(Brodmann and Riesterer 2008, Vollenweider 2008) as well as the MRI analysis (Hilfiker
2008) performed in August 2008 revealed the presence of two masses of about 4 mm in
agreement with our prediction.
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4. Discussion
Our result seems to be at variance with what is widely accepted as a “universal law”
(Schabel 1999, DeWys 1972, Norton et al 1976, Torkington 1983, Iwata et al 2000, Guiot
et al 2005, Delsanto et al 2004, Bru´ et al 2003, Kohandel et al 2007) describing tumor
growth, namely the “Gompertzian” growth curve. This curve is believed to describe
a gradual slowdown and eventual saturation in the growth of diverse populations from
bacteria (Zwietering et al 1990) to tumors and cell cultures (Norton et al 1976) to
natural populations in the wild. It is commonly ascribed to a limiting “carrier capacity”
of the environment, resulting in an inhibitory feedback of each new birth upon the rate
of multiplication, due, say to depletion of nutrients (Zwietering et al 1990) or oxygen
(Kohandel et al 2007) or some other vitally important agent. Mathematically, this effect
can be mimicked by introducing a rate of reproduction which decreases in time, as a
function of the actual population. This behavior was first mathematically described by
Gompertz (1825). Although the precise mechanism of the slowdown in the case of tumor
growth is still not totally clear, it is often characterized as obeying the Gompertzian
growth law. This means an initial regime of exponential growth gradually slowing down
and finally saturating to a constant value. (The final stage is to be observed in vitro,
or in animal models.) One should remark that plotting the data reported in Table 1
directly on the set marked with circles appearing in Fig. 3 of Norton et al (1976) (after
appropriately rescaling in the horizontal and vertical directions) results in an extremely
good fit with the “predicted” Gompertzian growth curve. This agreement suggests
plotting similar sets of data on a log-log scale, to possibly reveal a sharp crossover from
exponential to power law behavior in these sets as well.
5. Conclusion
It is well known (Kohandel et al 2007, Norton et al 1976, Guiot et al 2005) that the
initial stages of growth of many tumors, whether in vivo or in vitro, follow an exponential
growth curve. This regime corresponds to dispersed particles that can grow without
restriction. The crossover to a slower, power-law regime may be a manifestation of
cluster growth, i.e., individual cells coagulate and become macroscopic structures with
distinct surfaces. The clusters can be detected by some standard imaging techniques.
Indeed, the presence of at least two small, but distinct masses was verified in the present
case, after the onset of the power law growth regime.
Radiation therapy is not routinely applied after the surgery. The predictive power
of our simple analysis, however, makes it highly worthwhile to closely monitor the PSA
scores during the so-called wait-and-watch period no matter how low their absolute
value is, as has been done in the present case, in order not to miss the optimum time
window for post-operative therapy to increase the life expectancy of the cancer patient.
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